Reduced folate receptor alpha ( FOLR1 ) protein expression in fallopian tubes from premenopausal women: implications for the FOLR1 CDx assay for mirvetuximab‐soravtansine therapy
The Journal of Pathology: Clinical Research · 2026-05 · 12 (3)
DOI: 10.1002/2056-4538.70091 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 23.04.2026. Verfasst von Annika Nasdala und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Folate Receptor 1, Premenopause, Immunoconjugates, Fallopian Tubes. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mirvetuximab‐soravtansine (MIRV‐S) is an antibody‐drug conjugate targeting folate receptor alpha (FOLR1). MIRV‐S is approved for the treatment of FOLR1‐positive, platinum‐resistant ovarian carcinoma. Patient eligibility is determined by immunohistochemistry (IHC) using a companion diagnostic (CDx) assay (FOLR1‐2.1, Ventana). This assay requires on‐slide positive controls (OPCs) to aid FOLR1 evaluation. The manufacturer recommends normal fallopian tube (NFT) tissue for OPCs. Estrogen receptor signaling represses FOLR1 in cell culture models. It is unknown whether hormonal factors, such as menopausal status, also impact on FOLR1 immunoreactivity in NFTs used as OPCs. To address this question, we studied FOLR1 protein expression in NFTs (n = 51) from women aged 26–83 years. IHC was performed with the FOLR1‐2.1 CDx assay. Immunoreactivity at apical and basolateral cell membranes was assessed using H‐scores (aH‐score and bH‐score respectively). Overall FOLR1 expression was evaluated using a combined H‐score (cH‐score; i.e. aH‐ and bH‐scores added together). Immunoreactivity scores in pre‐, peri‐, and postmenopausal age groups were compared with the chi‐square test for trends. NFTs showed variable FOLR1 protein expression [median aH‐score: 152.5, interquartile range (IQR): 120–175; median bH‐score: 35, IQR: 7–85; median cH‐score: 195, IQR: 140–245]. Apical immunoreactivity was age‐independent ( p = 0.619), but low or absent basolateral immunoreactivity (bH‐score
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, Hannover Medical School, Hannover, Germany.
- Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany.
ORCID-Profile: Martin Radner, Matthias Christgen
Zitieren
APA
Nasdala, A., Kandt, L. D., Radner, M., Schaumann, N., Gronewold, M., Hillmann, P., Christgen, H., Hachenberg, J., Kuehnle, E., Hartmann, C., & Christgen, M. (2026). Reduced folate receptor alpha ( FOLR1 ) protein expression in fallopian tubes from premenopausal women: implications for the FOLR1 CDx assay for mirvetuximab‐soravtansine therapy. The Journal of Pathology: Clinical Research, 12(3). https://doi.org/10.1002/2056-4538.70091
Vancouver
Nasdala A, Kandt LD, Radner M, Schaumann N, Gronewold M, Hillmann P, et al. Reduced folate receptor alpha ( FOLR1 ) protein expression in fallopian tubes from premenopausal women: implications for the FOLR1 CDx assay for mirvetuximab‐soravtansine therapy. The Journal of Pathology: Clinical Research. 2026;12(3). doi:10.1002/2056-4538.70091
BibTeX
@article{Nasdala2026,
author = {Nasdala, Annika and Kandt, Leonie D and Radner, Martin and Schaumann, Nora and Gronewold, Malte and Hillmann, Pia and Christgen, Henriette and Hachenberg, Jens and Kuehnle, Elna and Hartmann, Christian and Christgen, Matthias},
title = {Reduced folate receptor alpha ( FOLR1 ) protein expression in fallopian tubes from premenopausal women: implications for the FOLR1 CDx assay for mirvetuximab‐soravtansine therapy},
journal = {The Journal of Pathology: Clinical Research},
year = {2026},
volume = {12},
number = {3},
doi = {10.1002/2056-4538.70091}
}
EUVIMED